Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001564590-17-007067
Filing Date
2017-04-25
Accepted
2017-04-24 21:55:36
Documents
4
Effectiveness Date
2017-04-25

Document Format Files

Seq Description Document Type Size
1 DEFA14A atra-defa14a_20171231.htm DEFA14A 28195
2 GRAPHIC g20170425014741054533.jpg GRAPHIC 20438
3 GRAPHIC g20170425014741028532.jpg GRAPHIC 68425
4 GRAPHIC g20170425014741002531.jpg GRAPHIC 47208
  Complete submission text file 0001564590-17-007067.txt   217011
Mailing Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-278-8930
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

EIN.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36548 | Film No.: 17779469
SIC: 2836 Biological Products, (No Diagnostic Substances)